Analytical Treatment Interruption

OTHER5 trials

Sponsors

Rockefeller University, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV InfectionHuman Immunodeficiency VirusHuman Immunodeficiency Virus (HIV)

Phase 1

3BNC117 and 10-1074 in HIV-infected Individuals

CompletedNCT02825797

Rockefeller UniversityHuman Immunodeficiency Virus (HIV)

Start: 2016-06-30End: 2018-08-15Updated: 2018-08-21

3BNC117 and 10-1074 in ART-treated Individuals

CompletedNCT03526848

Rockefeller UniversityHuman Immunodeficiency Virus

Start: 2018-06-05End: 2022-02-11Updated: 2025-10-01

Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

Enrolling by invitationNCT06908083

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2025-09-08End: 2028-06-30Target: 50Updated: 2026-03-10

Unknown Phase

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

CompletedNCT04801758

HIV Vaccine Trials NetworkHIV Infection

Start: 2022-08-22End: 2024-07-22Updated: 2025-04-20

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

CompletedNCT04860323

HIV Vaccine Trials NetworkHIV Infection

Start: 2021-05-28End: 2025-02-04Updated: 2026-03-13

Related Papers

Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data

Journal of the International AIDS Society2025-06-012 citations

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

2018-09-26219 citations